Related Experiment Video
Updated: May 12, 2026
02:20
Application of Mid-Pancreatectomy with End-to-End Anastomosis in Pancreatic Benign Tumors
Published on: February 9, 2024
[Pancreatectomy for the pancreatic tumors]
Khirurgiia
|April 25, 2013
Summary
Pancreatectomy for pancreatic tumors showed varied outcomes. While duct adenocarcinoma had a median survival of 7 months, other pancreatic tumors ranged from 6-36 months post-surgery.
Area of Science:
- Surgical Oncology
- Gastroenterology
- Pathology
Background:
- Pancreatic tumors necessitate surgical intervention, with pancreatectomy being a key procedure.
- Tumor type and extent significantly influence surgical indications and patient outcomes.
Purpose of the Study:
- To analyze the outcomes of pancreatectomies performed for various pancreatic tumors between 2009 and 2012.
- To evaluate the impact of tumor type and surgical contraindications on patient survival.
Main Methods:
- Retrospective analysis of 23 pancreatectomy cases for diverse pancreatic neoplasms.
- Detailed review of surgical indications, including tumor invasion and multifocality.
- Documentation of postoperative complications, mortality, and survival data based on tumor histology.
Main Results:
- Duct adenocarcinoma (15 cases) had a median survival of 7 months.
- Neuroendocrine neoplasms (4 cases), intraductal papillary-mucinous tumors (2 cases), renal-cell carcinoma metastasis (1 case), and serous cystadenoma (1 case) showed survival ranging from 6-36 months.
- Postoperative complications occurred in 43.5% of patients, with 2 deaths.
Conclusions:
- Pancreatectomy is a viable option for various pancreatic tumors, but outcomes vary significantly by histology.
- Contraindications for pancreatectomy differed between adenocarcinoma and neuroendocrine lesions, impacting surgical decisions.
- Careful patient selection and consideration of tumor biology are crucial for optimizing pancreatectomy outcomes.
